This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 3
  • /
  • Gilead + Merck announce agreement to jointly devel...
News

Gilead + Merck announce agreement to jointly develop and commercialize long-acting, investigational treatment combinations of lenacapavir and islatravir in HIV.

Read time: 1 mins
Published:16th Mar 2021
- Gilead Sciences, Inc. and Merck Inc., announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV. The companies will try to make oral and injectable treatments comprised of Gilead's lenacapavir and Merck's islatravir. Gilead will shoulder 60% of the development and commercialization costs while Merck supplies the other 40%. The companies will also split marketing responsibilities based on formulation, with Gilead taking the lead for long-acting oral products in the U.S. and long-acting injectable products in the rest of the world, and Merck vice versa. The first clinical studies of the oral combination are expected to begin in the second half of 2021. Under the terms of the agreement, Gilead and Merck will work as partners, sharing operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. The first clinical studies of the oral combination are expected to begin in the second half of 2021. Under the terms of the agreement, Gilead and Merck will work as partners, sharing operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues.
Condition: HIV/AIDS
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights